On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- A very old disease
- Outline
- Discovery of streptomycin and the first RCT
- The streptomycin trial: the 6 month results
- The streptomycin trial: the 5 year results
- Streptomycin and PAS
- The acquisition of streptomycin resistance
- Streptomycin, PAS and isoniazid
- Changes in mortality from TB in the UK
- From research to practice
- MRC chronic trial
- Results of the MRC chronic trial
- The advent of short course chemotherapy
- Short course chemotherapy: the first trial
- First East African short course trial
- How could these results best be compared?
- The non inferiority design
- Non-inferiority: first East African trial analysis
- First East African short course study
- The search for cheap but effective regimens
- Treatment from 1972 to 2010
- If 6 months works, why not 4?
- Fourth East African short course
- Trying again
- Slow to adopt
- Still waiting
- Two unanswered questions
- Treatment duration issues
- Intermittent chemotherapy (1)
- Intermittent chemotherapy (2)
- New cases of tuberculosis in Zambia
- Association between HIV and TB
- Treatment duration issues for HIV coinfection (1)
- Treatment duration issues for HIV coinfection (2)
- The need for programmed based trials
- Sahara study
- Treating refugees in a war zone
- The slow road to TB diagnosis
- Smear negative disease
- New regimens (the role of the mouse)
- How do we choose the regimens to phase III?
- MAMS (multi-arm multi-stage) trials
- Phase III TB trials
- The role of observational data
- "A gulf which has been much underestimated"
- East African and other drug resistance surveys
- Kenya RCT programme results
- Treating multidrug resistant TB
- The STREAM trial
- One drug - one shot in the dark?
Topics Covered
- Early trials demonstrated the need for giving more than one drug to avoid the problems of acquired drug resistance
- Short course chemotherapy highly effective provided rifampicin given throughout
- HIV coinfection has presented new challenges to effective treatment
- New methods needed to identify potential regimen candidates for phase III
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Nunn, A. (2013, February 28). The development of current treatments for tuberculosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/QGHY7370.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Andrew Nunn has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.